重新利用SGLT2抑制剂治疗肝炎:从机械研究到临床探索
Yuan Gao1, Yunyi Gao2, Dong Ji3
1Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Journal of clinical and translational hepatology
|March 11, 2026
概括
选择性SGLT2抑制剂通过向脏留,显示出对治疗肝硬化的有希望. 这些药物可以减少肝硬化患者的和脱补偿事件.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝硬化结是由于门高血压和神经激素激活导致脏水保留的结果.
- 在这个过程中,由/交换器3 (NHE3) 介导的近接管状再吸收是至关重要的.
- NHE3和-葡萄糖共运输体2 (SGLT2) 的空间合表明了治疗目标.
研究的目的:
- 审查SGLT2抑制剂在肝硬化瘤中的分子机制.
- 评估SGLT2抑制剂在治疗肝硬化炎中的新兴临床证据.
主要方法:
- 对将SGLT2抑制与NHE3活性联系起来的分子机制的审查.
- 早期临床研究的分析,包括病例报告,回顾性研究和试点随机试验.
主要成果:
- 抑制SGLT2抑制了NHE3的活性,减少了的再吸收.
- 增加化向斑点密度的输送调节了管球体反和氨酸-氨酸-阿尔多斯特系统.
- 早期的研究表明,在炎控制和减少脱补偿事件方面存在潜在的益处,尽管受到小样本大小和观察设计的限制.
结论:
- SGLT2 抑制剂代表了肝硬化的潜在治疗策略.
- 需要进一步的强有力的临床试验来确认疗效和通用性.
- 了解SGLT2,NHE3和脏生理学的相互作用是优化治疗的关键.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
307
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307
Secondary Active Transport
12.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
12.7K
Secondary Active Transport
139.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
139.7K
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
247
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247


